SanBio
SanBio Co Ltd is a Japanese-American biopharmaceutical company developing regenerative cell therapies for central nervous system disorders. The company advances its lead cell therapy product SB623 (vandefitemcel), composed of modified bone marrow-derived mesenchymal stem cells designed to promote neural regeneration following traumatic brain injury (TBI) and stroke. Main revenue drivers comprise milestone payments from licensing partners, commercial product sales of SB623 upon regulatory approvals, and research development grants. SanBio serves neurosurgeons, neurologists, rehabilitation centers, and patients suffering from traumatic brain injury and stroke across Japan and North America. The company holds a market-leading position in regenerative medicine for central nervous system nerve repair. Headquartered in Tokyo, Japan, SanBio Co Ltd is listed on the Tokyo Stock Exchange.
2 of the funds FundTelligence covers report a position in SanBio.
- Legal name
- SanBio Co Ltd
- Sector
- Health Care
- Country
- Japan
- Funds holding it
- 2
Funds holding SanBio
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.01 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.0 % (partially disclosed portfolio, June 2026)